Amgen Inc. (NASDAQ:AMGN) is one of the 10 best stocks to invest in during a recession. On February 27, 2026, Amgen Inc. (NASDAQ:AMGN)’s Phase 3 study (NCT05907122) saw an update. The study ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

More than 5000 Australians struggling with rare and advanced cancers will be able to access two new immunotherapy drugs for ...

From today, thousands more Australians living with advanced and rare cancers will have access to affordable immunotherapy treatment options through ...

FDA approves Opdivo and Yervoy for unresectable or metastatic MSI-H/dMMR colorectal cancer in patients 12 and older. Opdivo's accelerated approval for single-agent use in MSI-H/dMMR metastatic CRC is ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...

A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to keeping ...

LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's (FDA) approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...